ACLARION INC

NASDAQ: ACONW (Aclarion Inc)

Kemas kini terakhir: 16 jam lalu

0.029

0.01 (35.51%)

Penutupan Terdahulu 0.021
Jumlah Dagangan 70,421
Julat 52 Minggu
0.024 (-18%) — 0.029 (0%)
Margin Operasi (TTM) -10,789.22%
EPS Cair (TTM) -6.58
Pertumbuhan Hasil Suku Tahunan (YOY) 78.10%
Jumlah Hutang/Ekuiti (D/E MRQ) 47.32%
Nisbah Semasa (MRQ) 14.17
Aliran Tunai Operasi (OCF TTM) -8.95 M
Aliran Tunai Bebas Leveraj (LFCF TTM) -5.60 M
Pulangan Atas Aset (ROA TTM) -45.78%
Pulangan Atas Ekuiti (ROE TTM) -74.07%

AISkor Stockmoo

-0.4
Hutang rendah. Keuntungan lemah. Kecairan jangka pendek mencukupi. Aliran tunai negatif. info
Daripada penilaian laporan AI Insight kami tentang pulangan dijangka berbanding risiko. info NA
Penilaian Relatif info NA
Pertumbuhan Tersirat info NA
Sejarah Penilaian info NA
Pulangan atas Modal info NA
Trend Perolehan info NA
Nilai Pegangan info NA
Premium Risiko info NA
Penilaian Pasaran info NA
Daripada analisis teknikal AI kami terhadap carta. info NA
Kekuatan Aliran info NA
Persediaan Teknikal info NA
Corak Lilin info NA
Aliran Jangka Sederhana info NA
Tiada harga sasaran terkini, jadi berdasarkan arah semakan harga sasaran. info
Sentimen Pegangan info NA
Sentimen Berita info NA
Kedudukan jual singkat +16.8% dari 31 Aug hingga 30 Oct 2026, 7.1 hari untuk tutup (FINRA). info
Aktiviti Orang Dalam info NA
Aliran Institusi info NA
Persekitaran pasaran berhati-hati. info
Sektor mengatasi prestasi pasaran.
Hanya satu tonggak mempunyai bacaan yang jelas, jadi skor tidak berubah.
Volatiliti Harga info NA
Tiada aliran jelas bagi jangka pendek, sederhana dan panjang. info
Tiada isyarat jelas daripada sokongan dan rintangan. info
Skor Akhir -0.39
Tunjuk semua

Arah Aliran Pasaran

Jangka Pendek Jangka Sederhana
Industri Health Information Services (US) Bercampur Menurun
Health Information Services (Global) Bercampur Menurun
Stok Aclarion Inc - -

Saham Serupa

Stok Modal Pasaran DY P/E (TTM) P/B Skor
ACONW - - - - -0.4
CARL 477 M - - 6.29 1.6
SY 166 M - - 0.770 -2.9
OTRKP - - - - -2.9
TEM 10 B - - 19.68 -0.1
HQY 8 B - 34.21 4.05 0.0

Aclarion, Inc., a healthcare technology company, leverages for Magnetic Resonance Spectroscopy (MRS) in the United States. The company develops NOCISCAN Post-Processor suite of software applications comprising NOCICALC that receives the raw un-processed NOCISCAN MRS exam data and post-processes that raw data into final spectra and performs various degenerative pain biomarker; and NOCIGRAM, a clinical decision support software. The company was formerly known as Nocimed, Inc. and changed its name to Aclarion, Inc. in December 2021. Aclarion, Inc. was founded in 2008 and is based in Broomfield, Colorado.

Sektor Healthcare
Industri Health Information Services

Pemilikan

Nama Tarikh Syer Dipegang
Captrust Financial Advisors 30 Sep 2026 63,400

Tiada data dalam julat masa ini.

Institusi

Kedudukan Jual Singkat

Penyelesaian Saham Hari untuk tutup
30 Oct 2026 81,593 7.1
15 Oct 2026 73,843 4.2
30 Sep 2026 67,490 5.6
15 Sep 2026 66,327 27.1
31 Aug 2026 69,875 8.3
14 Aug 2026 231,797 4.2

Data jual singkat FINRA melalui Nasdaq, dilaporkan dua kali sebulan.

Tarikh Jenis Butiran
28 Oct 2026 Yahoo Finance Bausch + Lomb (BLCO) Surpasses Q3 Earnings and Revenue Estimates
Bausch + Lomb (BLCO) delivered earnings and revenue surprises of +61.91% and +0.14%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
27 Oct 2026 Yahoo Finance HCA Healthcare (HCA) Q3 Earnings and Revenues Top Estimates
HCA (HCA) delivered earnings and revenue surprises of +7.12% and +2.50%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
22 Oct 2026 Yahoo Finance Aclarion Announces New Real-World Publication: Nociscan® Validated by Strong Agreement with Discography in Diagnosing Painful Lumbar Discs
Study conducted at London Spine Clinic found Nociscan's noninvasive scan successfully identified painful discs, agreeing with discography, the invasive gold standard, in up to 87% of casesNociscan also spared patients the needles, added cost, and recovery time that is often associated with…
20 Oct 2026 Yahoo Finance Aclarion Publishes CEO Shareholder Letter Highlighting Continued Scan Volume Growth and Advancing Clinical Program in Third Quarter 2026
85% year-over-year scan volume growth in Q3 2026, contributing to 117% growth for the nine months ended September 30, 2026European Spine Journal publishes peer-reviewed data supporting MRS as a potential viable alternative to provocative discographyCLARITY trial expanded to eleven clinical sites…
13 Oct 2026 Yahoo Finance Aclarion to Present at the 20th Annual LD Micro Main Event
BROOMFIELD, Colo., Oct. 13, 2026 (GLOBE NEWSWIRE) -- Aclarion (NASDAQ: ACON) announced today that it will participate in the 20th Annual LD Micro Main Event, taking place October 19-21, 2026 at the Luxe Sunset Boulevard Hotel in Los Angeles, California. Aclarion is scheduled to present on Tuesday…
08 Oct 2026 Yahoo Finance Aclarion Broadens CLARITY Trial Enrollment Criteria to Accelerate Enrollment
New criteria fully approved at nine of eleven active sites expected to significantly accelerate enrollment paceInitial readout timing to be updated by year-end based on demonstrated Q4 enrollment increasesOverall trial duration remains on track BROOMFIELD, Colo., Oct. 08, 2026 (GLOBE NEWSWIRE)…
29 Sep 2026 Yahoo Finance Aclarion Welcomes NYU Langone Health to CLARITY Trial Network, Now Enrolling at Eleven Sites
NYU Langone Health is a nationally recognized academic medical center with deep expertise in spine surgery, minimally invasive procedures, robotic spine surgery, and clinical researchCLARITY is a prospective, randomized clinical trial designed to demonstrate Nociscan’s ability to improve surgical…

Portfolio

AI Templat

Peringatan harga anda

Profil Risiko

| | | | |
Konservatif
Sederhana Konservatif
Sederhana
Sederhana Agresif
Agresif
Margin Keselamatan (EP)
Keuntungan Separa (TP1)
Keuntungan Sasaran (TP2)
Kerugian Maksimum (SL)

Penafian: Perkara di atas adalah untuk tujuan ilustrasi sahaja dan BUKAN nasihat pelaburan. Dapatkan nasihat daripada penasihat kewangan yang berkelayakan.

Harga Masuk (EP)

Ambil Untung 1 (TP1)

Ambil Untung 2 (TP2)

Henti Rugi (SL)

Risiko / Ganjaran
TP1:
TP2:

Kerugian hingga SL berbanding keuntungan hingga setiap sasaran, dari EP. Nisbah 2 atau lebih biasanya dicari.

Julat 52 Minggu
 
52WL
 
52WH
SL
EP
TP1
TP2

Semua harga peringatan berada dalam julat harga 52 minggu

Keuntungan Nyata -
Keuntungan Tidak Nyata -
Dividen Diterima 2026 -
Jumlah Untung -
Pulangan Purata -
Kuantiti (Beli) -
Purata Harga (Beli) -
Kuantiti (Jual) -
Purata Harga (Jual) -
Tiada saham yang memenuhi kriteria anda